Home

Download

Statistics

Examples

Help

Contact

Fusion Protein:CERS6-ZC3H15

Fusion Gene and Fusion Protein Summary

Fusion gene summary

Fusion partner gene information	Fusion gene name: CERS6-ZC3H15
	FusionPDB ID: 16011
	FusionGDB2.0 ID: 16011
		Hgene	Tgene
	Gene symbol	CERS6	ZC3H15
	Gene ID	253782	55854
	Gene name	ceramide synthase 6	zinc finger CCCH-type containing 15
	Synonyms	CERS5\|LASS6	HT010\|LEREPO4\|MSTP012
	Cytomap	2q24.3	2q32.1
	Type of gene	protein-coding	protein-coding
	Description	ceramide synthase 6LAG1 homolog, ceramide synthase 6longevity assurance homolog 6	zinc finger CCCH domain-containing protein 15DRG family-regulatory protein 1likely ortholog of mouse immediate early response erythropoietin 4
	Modification date	20200313	20200313
	UniProtAcc	Q6ZMG9 Main function of 5'-partner protein: FUNCTION: Ceramide synthase that catalyzes formation of ceramide from sphinganine and acyl-CoA substrates, with high selectivity toward palmitoyl-CoA (hexadecanoyl-CoA; C16:0-CoA) as acyl donor (PubMed:17977534, PubMed:17609214, PubMed:23530041, PubMed:26887952, PubMed:31916624). Can use other acyl donors, but with less efficiency (By similarity). Ceramides generated by CERS6 play a role in inflammatory response (By similarity). Acts as a regulator of metabolism and hepatic lipid accumulation (By similarity). Under high fat diet, palmitoyl- (C16:0-) ceramides generated by CERS6 specifically bind the mitochondrial fission factor MFF, thereby promoting mitochondrial fragmentation and contributing to the development of obesity (By similarity). {ECO:0000250\|UniProtKB:Q8C172, ECO:0000269\|PubMed:17609214, ECO:0000269\|PubMed:17977534, ECO:0000269\|PubMed:23530041, ECO:0000269\|PubMed:26887952, ECO:0000269\|PubMed:31916624}.	.
Ensembl transtripts involved in fusion gene	ENST ids	ENST00000305747, ENST00000392687,	ENST00000468120, ENST00000544130, ENST00000337859,
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)	* DoF score	18 X 12 X 8=1728	5 X 5 X 2=50
	# samples	22	5
	** MAII score	log2(22/1728*10)=-2.97352778863881 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0	log2(5/50*10)=0
Fusion gene context	PubMed: CERS6 [Title/Abstract] AND ZC3H15 [Title/Abstract] AND fusion [Title/Abstract]
Fusion neoantigen context	PubMed: CERS6 [Title/Abstract] AND ZC3H15 [Title/Abstract] AND neoantigen [Title/Abstract]
Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)	CERS6(169487552)-ZC3H15(187359960), # samples:1
Anticipated loss of major functional domain due to fusion event.	CERS6-ZC3H15 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. CERS6-ZC3H15 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. CERS6-ZC3H15 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. CERS6-ZC3H15 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.

* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez

Partner	Gene	GO ID	GO term	PubMed ID
Hgene	CERS6	GO:0046513	ceramide biosynthetic process	17609214\|17977534
Tgene	ZC3H15	GO:0043547	positive regulation of GTPase activity	23711155

Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr2:169487552/chr2:187359960)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.

Retention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

Fusion gene breakpoints across CERS6 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Fusion gene breakpoints across ZC3H15 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Top

Fusion Amino Acid Sequences

Fusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.

Henst

Tenst

Hgene

Hchr

Hbp

Hstrand

Tgene

Tchr

Tbp

Tstrand

Seq length
(transcript)

BP loci
(transcript)

Predicted start
(transcript)

Predicted stop
(transcript)

Seq length
(amino acids)

ENST00000305747

CERS6

chr2

169487552

ENST00000337859

ZC3H15

chr2

187359960

2888

1052

287

2257

656

ENST00000392687

CERS6

chr2

169487552

ENST00000337859

ZC3H15

chr2

187359960

2501

665

140

1870

576

DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	No-coding score	Coding score
ENST00000305747	ENST00000337859	CERS6	chr2	169487552	+	ZC3H15	chr2	187359960	+	0.001349213	0.99865085
ENST00000392687	ENST00000337859	CERS6	chr2	169487552	+	ZC3H15	chr2	187359960	+	0.001248822	0.99875116

Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for CERS6-ZC3H15

+/-13 AA sequence from the breakpoints of the fusion protein sequences.

Hgene	Hchr	Hbp	Tgene	Tchr	Tbp	Length(fusion protein)	BP in fusion protein	Peptide
CERS6	chr2	169487552	ZC3H15	chr2	187359960	1052	249	WRFSFYLYVFTYGVRFLKKDKTFGLK
CERS6	chr2	169487552	ZC3H15	chr2	187359960	665	169	WRFSFYLYVFTYGVRFLKKDKTFGLK

Top

Potential FusionNeoAntigen Information of CERS6-ZC3H15 in HLA I

Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.

CERS6-ZC3H15_169487552_187359960.msa

Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)

Fusion gene	Hchr	Hbp	Tgene	Tchr	Tbp	HLA I	FusionNeoAntigen peptide	Binding score	Immunogenic score	Neoantigen start (at BP 13)	Neoantigen end (at BP 13)
CERS6-ZC3H15	chr2	169487552	chr2	187359960	1052	HLA-B15:02	YVFTYGVRF	0.9933	0.8465	7	16
CERS6-ZC3H15	chr2	169487552	chr2	187359960	1052	HLA-A30:08	FTYGVRFLK	0.9923	0.6084	9	18
CERS6-ZC3H15	chr2	169487552	chr2	187359960	1052	HLA-B15:25	YVFTYGVRF	0.9921	0.8265	7	16
CERS6-ZC3H15	chr2	169487552	chr2	187359960	1052	HLA-B35:01	YVFTYGVRF	0.9796	0.808	7	16
CERS6-ZC3H15	chr2	169487552	chr2	187359960	1052	HLA-B15:01	YVFTYGVRF	0.9783	0.795	7	16
CERS6-ZC3H15	chr2	169487552	chr2	187359960	1052	HLA-B15:17	YVFTYGVRF	0.9709	0.7128	7	16
CERS6-ZC3H15	chr2	169487552	chr2	187359960	1052	HLA-A02:04	YLYVFTYGV	0.97	0.5201	5	14
CERS6-ZC3H15	chr2	169487552	chr2	187359960	1052	HLA-B15:03	YVFTYGVRF	0.9213	0.5363	7	16
CERS6-ZC3H15	chr2	169487552	chr2	187359960	1052	HLA-A32:13	YVFTYGVRF	0.8158	0.7151	7	16
CERS6-ZC3H15	chr2	169487552	chr2	187359960	1052	HLA-A30:08	VFTYGVRFLK	0.9744	0.6462	8	18
CERS6-ZC3H15	chr2	169487552	chr2	187359960	1052	HLA-C15:04	FTYGVRFL	0.9997	0.8455	9	17
CERS6-ZC3H15	chr2	169487552	chr2	187359960	1052	HLA-C03:19	FTYGVRFL	0.9997	0.9561	9	17
CERS6-ZC3H15	chr2	169487552	chr2	187359960	1052	HLA-C03:08	FTYGVRFL	0.9997	0.8171	9	17
CERS6-ZC3H15	chr2	169487552	chr2	187359960	1052	HLA-C15:06	FTYGVRFL	0.9995	0.8774	9	17
CERS6-ZC3H15	chr2	169487552	chr2	187359960	1052	HLA-C03:07	FTYGVRFL	0.9983	0.9652	9	17
CERS6-ZC3H15	chr2	169487552	chr2	187359960	1052	HLA-C12:12	FTYGVRFL	0.9929	0.888	9	17
CERS6-ZC3H15	chr2	169487552	chr2	187359960	1052	HLA-C06:03	FTYGVRFL	0.9821	0.9859	9	17
CERS6-ZC3H15	chr2	169487552	chr2	187359960	1052	HLA-C12:04	FTYGVRFL	0.9819	0.9872	9	17
CERS6-ZC3H15	chr2	169487552	chr2	187359960	1052	HLA-C02:06	FTYGVRFL	0.9662	0.9617	9	17
CERS6-ZC3H15	chr2	169487552	chr2	187359960	1052	HLA-B15:21	YVFTYGVRF	0.9937	0.8176	7	16
CERS6-ZC3H15	chr2	169487552	chr2	187359960	1052	HLA-B15:31	YVFTYGVRF	0.9803	0.7325	7	16
CERS6-ZC3H15	chr2	169487552	chr2	187359960	1052	HLA-B15:05	YVFTYGVRF	0.9762	0.73	7	16
CERS6-ZC3H15	chr2	169487552	chr2	187359960	1052	HLA-C03:07	YVFTYGVRF	0.9289	0.9272	7	16
CERS6-ZC3H15	chr2	169487552	chr2	187359960	1052	HLA-C15:04	YVFTYGVRF	0.9283	0.7554	7	16
CERS6-ZC3H15	chr2	169487552	chr2	187359960	1052	HLA-C12:12	YVFTYGVRF	0.816	0.8546	7	16
CERS6-ZC3H15	chr2	169487552	chr2	187359960	1052	HLA-C04:06	YVFTYGVRF	0.7355	0.5942	7	16
CERS6-ZC3H15	chr2	169487552	chr2	187359960	1052	HLA-C03:14	YVFTYGVRF	0.6525	0.9128	7	16
CERS6-ZC3H15	chr2	169487552	chr2	187359960	1052	HLA-C12:04	YVFTYGVRF	0.6232	0.9639	7	16
CERS6-ZC3H15	chr2	169487552	chr2	187359960	1052	HLA-C06:03	YVFTYGVRF	0.6051	0.9643	7	16
CERS6-ZC3H15	chr2	169487552	chr2	187359960	1052	HLA-C15:09	FTYGVRFL	0.9997	0.8455	9	17
CERS6-ZC3H15	chr2	169487552	chr2	187359960	1052	HLA-C03:03	FTYGVRFL	0.9997	0.9819	9	17
CERS6-ZC3H15	chr2	169487552	chr2	187359960	1052	HLA-C03:04	FTYGVRFL	0.9997	0.9819	9	17
CERS6-ZC3H15	chr2	169487552	chr2	187359960	1052	HLA-C03:05	FTYGVRFL	0.9993	0.7678	9	17
CERS6-ZC3H15	chr2	169487552	chr2	187359960	1052	HLA-C03:17	FTYGVRFL	0.9992	0.9419	9	17
CERS6-ZC3H15	chr2	169487552	chr2	187359960	1052	HLA-C15:05	FTYGVRFL	0.9992	0.7752	9	17
CERS6-ZC3H15	chr2	169487552	chr2	187359960	1052	HLA-C15:02	FTYGVRFL	0.999	0.8493	9	17
CERS6-ZC3H15	chr2	169487552	chr2	187359960	1052	HLA-C16:04	FTYGVRFL	0.9989	0.9588	9	17
CERS6-ZC3H15	chr2	169487552	chr2	187359960	1052	HLA-C12:03	FTYGVRFL	0.9969	0.9664	9	17
CERS6-ZC3H15	chr2	169487552	chr2	187359960	1052	HLA-C12:02	FTYGVRFL	0.9961	0.967	9	17
CERS6-ZC3H15	chr2	169487552	chr2	187359960	1052	HLA-C16:01	FTYGVRFL	0.9942	0.9488	9	17
CERS6-ZC3H15	chr2	169487552	chr2	187359960	1052	HLA-C06:17	FTYGVRFL	0.9921	0.9865	9	17
CERS6-ZC3H15	chr2	169487552	chr2	187359960	1052	HLA-C06:02	FTYGVRFL	0.9921	0.9865	9	17
CERS6-ZC3H15	chr2	169487552	chr2	187359960	1052	HLA-C16:02	FTYGVRFL	0.9807	0.9794	9	17
CERS6-ZC3H15	chr2	169487552	chr2	187359960	1052	HLA-C02:10	FTYGVRFL	0.9597	0.9707	9	17
CERS6-ZC3H15	chr2	169487552	chr2	187359960	1052	HLA-C02:02	FTYGVRFL	0.9597	0.9707	9	17
CERS6-ZC3H15	chr2	169487552	chr2	187359960	1052	HLA-C14:03	VFTYGVRF	0.9452	0.8955	8	16
CERS6-ZC3H15	chr2	169487552	chr2	187359960	1052	HLA-C14:02	VFTYGVRF	0.9452	0.8955	8	16
CERS6-ZC3H15	chr2	169487552	chr2	187359960	1052	HLA-C06:08	FTYGVRFL	0.9242	0.986	9	17
CERS6-ZC3H15	chr2	169487552	chr2	187359960	1052	HLA-C17:01	FTYGVRFL	0.8995	0.6008	9	17
CERS6-ZC3H15	chr2	169487552	chr2	187359960	1052	HLA-A30:01	FTYGVRFLK	0.9921	0.7742	9	18
CERS6-ZC3H15	chr2	169487552	chr2	187359960	1052	HLA-B35:11	YVFTYGVRF	0.9918	0.8071	7	16
CERS6-ZC3H15	chr2	169487552	chr2	187359960	1052	HLA-B15:39	YVFTYGVRF	0.99	0.6581	7	16
CERS6-ZC3H15	chr2	169487552	chr2	187359960	1052	HLA-C03:03	YVFTYGVRF	0.9879	0.9652	7	16
CERS6-ZC3H15	chr2	169487552	chr2	187359960	1052	HLA-C03:04	YVFTYGVRF	0.9879	0.9652	7	16
CERS6-ZC3H15	chr2	169487552	chr2	187359960	1052	HLA-C03:67	YVFTYGVRF	0.9858	0.8943	7	16
CERS6-ZC3H15	chr2	169487552	chr2	187359960	1052	HLA-C03:02	YVFTYGVRF	0.9851	0.927	7	16
CERS6-ZC3H15	chr2	169487552	chr2	187359960	1052	HLA-B15:35	YVFTYGVRF	0.9816	0.7366	7	16
CERS6-ZC3H15	chr2	169487552	chr2	187359960	1052	HLA-B15:08	YVFTYGVRF	0.9813	0.7101	7	16
CERS6-ZC3H15	chr2	169487552	chr2	187359960	1052	HLA-B35:77	YVFTYGVRF	0.9796	0.808	7	16
CERS6-ZC3H15	chr2	169487552	chr2	187359960	1052	HLA-B15:33	YVFTYGVRF	0.9783	0.795	7	16
CERS6-ZC3H15	chr2	169487552	chr2	187359960	1052	HLA-B15:125	YVFTYGVRF	0.9783	0.795	7	16
CERS6-ZC3H15	chr2	169487552	chr2	187359960	1052	HLA-B15:34	YVFTYGVRF	0.9783	0.795	7	16
CERS6-ZC3H15	chr2	169487552	chr2	187359960	1052	HLA-B15:27	YVFTYGVRF	0.9782	0.8261	7	16
CERS6-ZC3H15	chr2	169487552	chr2	187359960	1052	HLA-B15:135	YVFTYGVRF	0.9777	0.7936	7	16
CERS6-ZC3H15	chr2	169487552	chr2	187359960	1052	HLA-B35:23	YVFTYGVRF	0.9777	0.7897	7	16
CERS6-ZC3H15	chr2	169487552	chr2	187359960	1052	HLA-B15:24	YVFTYGVRF	0.9766	0.6894	7	16
CERS6-ZC3H15	chr2	169487552	chr2	187359960	1052	HLA-B15:20	YVFTYGVRF	0.976	0.847	7	16
CERS6-ZC3H15	chr2	169487552	chr2	187359960	1052	HLA-B35:43	YVFTYGVRF	0.9757	0.7052	7	16
CERS6-ZC3H15	chr2	169487552	chr2	187359960	1052	HLA-B35:20	YVFTYGVRF	0.9742	0.8812	7	16
CERS6-ZC3H15	chr2	169487552	chr2	187359960	1052	HLA-A25:01	YVFTYGVRF	0.9675	0.5441	7	16
CERS6-ZC3H15	chr2	169487552	chr2	187359960	1052	HLA-B35:28	YVFTYGVRF	0.9657	0.8622	7	16
CERS6-ZC3H15	chr2	169487552	chr2	187359960	1052	HLA-C16:04	YVFTYGVRF	0.9388	0.9381	7	16
CERS6-ZC3H15	chr2	169487552	chr2	187359960	1052	HLA-C15:09	YVFTYGVRF	0.9283	0.7554	7	16
CERS6-ZC3H15	chr2	169487552	chr2	187359960	1052	HLA-C03:05	YVFTYGVRF	0.927	0.7092	7	16
CERS6-ZC3H15	chr2	169487552	chr2	187359960	1052	HLA-C12:02	YVFTYGVRF	0.9009	0.9272	7	16
CERS6-ZC3H15	chr2	169487552	chr2	187359960	1052	HLA-B15:12	YVFTYGVRF	0.8971	0.7336	7	16
CERS6-ZC3H15	chr2	169487552	chr2	187359960	1052	HLA-A32:01	YVFTYGVRF	0.8759	0.7281	7	16
CERS6-ZC3H15	chr2	169487552	chr2	187359960	1052	HLA-B35:24	YVFTYGVRF	0.8325	0.8361	7	16
CERS6-ZC3H15	chr2	169487552	chr2	187359960	1052	HLA-C12:03	YVFTYGVRF	0.8266	0.9273	7	16
CERS6-ZC3H15	chr2	169487552	chr2	187359960	1052	HLA-C07:17	YVFTYGVRF	0.8076	0.8825	7	16
CERS6-ZC3H15	chr2	169487552	chr2	187359960	1052	HLA-C03:67	VFTYGVRFL	0.2391	0.9765	8	17
CERS6-ZC3H15	chr2	169487552	chr2	187359960	1052	HLA-C02:10	YVFTYGVRF	0.0851	0.9431	7	16
CERS6-ZC3H15	chr2	169487552	chr2	187359960	1052	HLA-C02:02	YVFTYGVRF	0.0851	0.9431	7	16
CERS6-ZC3H15	chr2	169487552	chr2	187359960	1052	HLA-C14:02	VFTYGVRFL	0.0371	0.9285	8	17
CERS6-ZC3H15	chr2	169487552	chr2	187359960	1052	HLA-C14:03	VFTYGVRFL	0.0371	0.9285	8	17
CERS6-ZC3H15	chr2	169487552	chr2	187359960	1052	HLA-C06:06	VFTYGVRFL	0.0124	0.9778	8	17

Top

Potential FusionNeoAntigen Information of CERS6-ZC3H15 in HLA II

CERS6-ZC3H15_169487552_187359960.msa

Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).

Fusion gene	Hchr	Hbp	Tgene	Tchr	Tbp	HLA II	FusionNeoAntigen peptide	Neoantigen start (at BP 13)	Neoantigen end (at BP 13)
CERS6-ZC3H15	chr2	169487552	chr2	187359960	1052	DRB1-1111	YGVRFLKKDKTFGLK	11	26
CERS6-ZC3H15	chr2	169487552	chr2	187359960	1052	DRB1-1192	FTYGVRFLKKDKTFG	9	24
CERS6-ZC3H15	chr2	169487552	chr2	187359960	1052	DRB1-1192	TYGVRFLKKDKTFGL	10	25
CERS6-ZC3H15	chr2	169487552	chr2	187359960	1052	DRB1-1204	FTYGVRFLKKDKTFG	9	24
CERS6-ZC3H15	chr2	169487552	chr2	187359960	1052	DRB1-1209	FTYGVRFLKKDKTFG	9	24
CERS6-ZC3H15	chr2	169487552	chr2	187359960	1052	DRB1-1220	FTYGVRFLKKDKTFG	9	24
CERS6-ZC3H15	chr2	169487552	chr2	187359960	1052	DRB1-1363	YGVRFLKKDKTFGLK	11	26

Top

Fusion breakpoint peptide structures of CERS6-ZC3H15

3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.

File name	BPseq	Hgene	Tgene	Hchr	Hbp	Tchr	Tbp	AAlen
5844	LYVFTYGVRFLKKD	CERS6	ZC3H15	chr2	169487552	chr2	187359960	1052

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of CERS6-ZC3H15

Virtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.

HLA allele	PDB ID	File name	BPseq	Docking score	Glide score
HLA-B14:02	3BVN	5844	LYVFTYGVRFLKKD	-5.89991	-6.01331
HLA-B14:02	3BVN	5844	LYVFTYGVRFLKKD	-4.1331	-5.1684
HLA-B27:09	3CZF	5844	LYVFTYGVRFLKKD	10000.1	10000
HLA-B52:01	3W39	5844	LYVFTYGVRFLKKD	-5.79162	-5.90502
HLA-B52:01	3W39	5844	LYVFTYGVRFLKKD	-4.50212	-5.53742
HLA-B18:01	4JQV	5844	LYVFTYGVRFLKKD	-7.21332	-8.24862
HLA-B18:01	4JQV	5844	LYVFTYGVRFLKKD	-5.12387	-5.23727
HLA-A11:01	4UQ2	5844	LYVFTYGVRFLKKD	-8.65958	-8.77298
HLA-A11:01	4UQ2	5844	LYVFTYGVRFLKKD	-5.71034	-6.74564
HLA-A24:02	5HGA	5844	LYVFTYGVRFLKKD	-6.76463	-6.87803
HLA-A24:02	5HGA	5844	LYVFTYGVRFLKKD	-5.91906	-6.95436
HLA-B27:05	6PYJ	5844	LYVFTYGVRFLKKD	-5.96168	-6.99698
HLA-B27:05	6PYJ	5844	LYVFTYGVRFLKKD	-4.11716	-4.23056
HLA-B27:03	6PZ5	5844	LYVFTYGVRFLKKD	-4.97412	-6.00942
HLA-B27:03	6PZ5	5844	LYVFTYGVRFLKKD	-1.04645	-1.15985
HLA-B44:05	3DX8	5844	LYVFTYGVRFLKKD	-6.19701	-6.31041
HLA-B44:05	3DX8	5844	LYVFTYGVRFLKKD	-3.77766	-4.81296
HLA-A02:01	6TDR	5844	LYVFTYGVRFLKKD	-4.17517	-5.21047

Top

Vaccine Design for the FusionNeoAntigens of CERS6-ZC3H15

mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.

Fusion gene	Hchr	Hbp	Tchr	Tbp	Start in +/-13AA	End in +/-13AA	FusionNeoAntigen peptide sequence	FusionNeoAntigen RNA sequence
CERS6-ZC3H15	chr2	169487552	chr2	187359960	5	14	YLYVFTYGV	TACGGAGTCAGATTCCTGAAAAAGGAC
CERS6-ZC3H15	chr2	169487552	chr2	187359960	7	16	YVFTYGVRF	GTCAGATTCCTGAAAAAGGACAAAACT
CERS6-ZC3H15	chr2	169487552	chr2	187359960	8	16	VFTYGVRF	AGATTCCTGAAAAAGGACAAAACT
CERS6-ZC3H15	chr2	169487552	chr2	187359960	8	17	VFTYGVRFL	AGATTCCTGAAAAAGGACAAAACTTTC
CERS6-ZC3H15	chr2	169487552	chr2	187359960	8	18	VFTYGVRFLK	AGATTCCTGAAAAAGGACAAAACTTTCGGT
CERS6-ZC3H15	chr2	169487552	chr2	187359960	9	17	FTYGVRFL	TTCCTGAAAAAGGACAAAACTTTC
CERS6-ZC3H15	chr2	169487552	chr2	187359960	9	18	FTYGVRFLK	TTCCTGAAAAAGGACAAAACTTTCGGT

mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.

Fusion gene	Hchr	Hbp	Tchr	Tbp	Start in +/-13AA	End in +/-13AA	FusionNeoAntigen peptide	FusionNEoAntigen RNA sequence
CERS6-ZC3H15	chr2	169487552	chr2	187359960	10	25	TYGVRFLKKDKTFGL	CTGAAAAAGGACAAAACTTTCGGTTTGAAGAATAAGAAAGGAGCA
CERS6-ZC3H15	chr2	169487552	chr2	187359960	11	26	YGVRFLKKDKTFGLK	AAAAAGGACAAAACTTTCGGTTTGAAGAATAAGAAAGGAGCAAAG
CERS6-ZC3H15	chr2	169487552	chr2	187359960	9	24	FTYGVRFLKKDKTFG	TTCCTGAAAAAGGACAAAACTTTCGGTTTGAAGAATAAGAAAGGA

Top

Information of the samples that have these potential fusion neoantigens of CERS6-ZC3H15

These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.

Cancer type	Fusion gene	Hchr	Hbp	Henst	Tchr	Tbp	Tenst	Sample
STAD	CERS6-ZC3H15	chr2	169487552	ENST00000305747	chr2	187359960	ENST00000337859	TCGA-HU-A4GT-01A

Top

Potential target of CAR-T therapy development for CERS6-ZC3H15

Predicted 3D structure. We used RoseTTAFold.

Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features

* Minus value of BPloci means that the break point is located before the CDS.

- In-frame and retained 'Transmembrane'.

Partner

Gene

Hbp

Tbp

ENST

Strand

BPexon

TotalExon

Protein feature loci

*BPloci

TotalLen

Protein feature

Protein feature note

Hgene

CERS6

chr2:169487552

chr2:187359960

ENST00000305747

35_55

155

385.0

Transmembrane

Helical

Hgene

CERS6

chr2:169487552

chr2:187359960

ENST00000392687

35_55

155

393.0

Transmembrane

Helical

Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.

Hgene

Hchr

Hbp

Henst

Tgene

Tchr

Tbp

Tenst

DeepLoc result

Top

Related Drugs to CERS6-ZC3H15

Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Drug

Source

PMID

Top

Related Diseases to CERS6-ZC3H15

Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Disease

Source

PMID

Diseases associated with fusion partners.
(DisGeNet 4.0)

Partner

Gene

Disease ID

Disease name

# pubmeds

Source

	Fusion Gene and Fusion Protein Summary
	Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)
	Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)
	Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)
	Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)
	Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)
	Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)
	Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)
	Potential target of CAR-T therapy development
	Information on the samples that have these potential fusion neoantigens
	Fusion Protein Targeting Drugs - (Manual Curation)
	Fusion Protein Related diseases - (Manual Curation)